New Life Science VC Launches With €210m Fund
This article was originally published in Scrip
Index Ventures has spun off its life sciences team, portfolio companies and funds into a new venture capital firm called Medicxi Ventures, a validation of its 'asset-centric' approach to investing. The new firm launches with the close of Medicxi Ventures 1 (MV1), a new €210m ($250m) fund that will continue focusing on asset-centric, early-stage investments in European life science programs.
Register for our free email digests: